Monday, January 16, 2017

Sunbed users get melanoma at a younger age

Melanoma is the most dangerous type of skin cancer with the strongest increase in incidence in the last decade, and the incidence rates have never been as high as in 2014 (www.kreftregisteret.no). Now there are about 2,000 new cases of melanoma each year in Norway. The World Health Organization based International Agency for Research on Cancer has classified UV-emitting tanning devices as "carcinogenic to humans" in 2009 (www.iarc.fr). However, sunbed use is still popular in western countries, especially among young women.
New evidence on the damaging effect of sunbeds
The study followed 141,000 Norwegian women for the average of 14 years. Women who had 30 or more indoor tanning sessions were at 32% increased risk of melanoma compared to never-users. In addition, women who started indoor tanning before age 30 were on average 2 years younger at melanoma diagnosis than never-users. These associations remained significant after controlling for age, birth-cohort, ambient UV of residence, hair color, skin color, and cumulative number of sunburns and sunbathing vacations.
Public health importance
Modern sunbeds emit six times more UVA and twice as much UVB as Oslo summer sun. The findings of this study have important implications for public health, as it shows that sunbed use increases the burden of melanoma in societies by both increasing the number of patients and decreasing the age at diagnosis.

Story Source:
Materials provided by University of Oslo, Faculty of Medicine. Note: Content may be edited for style and length.

Markers for prostate cancer death can identify men in need of more aggressive treatment

Prostate cancer (PC) is the second leading cause of male cancer death in the United States with an estimated 26,000 deaths in 2016. Two-thirds of all PC deaths observed in the US are men with localized disease who developed metastasis. Several markers for dying from prostate cancer exist, but whether these are markers for telling who is likely to die early from any cause, and how their performance compares, is unknown. Identifying such a marker is important because we can then identify which men may benefit from new, more aggressive treatments for prostate cancer.
Researchers at Brigham and Women's Hospital found that a prostate specific antigen (PSA) nadir (the lowest level a PSA drops after treatment) greater than 0.5 ng/mL following radiation and androgen deprivation therapy (anti-hormone therapy), appears to identify men prior to PSA failure who are at high-risk for dying early as a result of treatment failure for their prostate cancer. The findings are published in the January 12 edition of JAMA Oncology.
"By identifying and enrolling these men in clinical trials immediately, the hope is to take a prostate cancer that appears to be incurable and make it curable" stated Trevor J. Royce, MD, senior resident in the department of Radiation Oncology at BWH, and corresponding author of the study.
Using data from a randomized trial of 206 men treated with either radiation or, radiation and six months of hormonal therapy, researchers compared early markers of prostate cancer death to identify men at risk of dying early.
"This study's results can have practice changing implications on how future prostate cancer trials are designed in terms of identifying the men for these studies who are at high risk for early death due to ineffective initial treatment for their prostate cancer," stated Anthony Victor D'Amico, MD, PhD, chief, Genitourinary Radiation Oncology, Brigham and Women's Hospital and senior author of the study.

Story Source:
Materials provided by Brigham and Women's Hospital. Note: Content may be edited for style and length.

Journal Reference:
  1. Royce, MD, MS et al. A Comparison of Surrogate Endpoints for All Cause Mortality in Men with Localized Unfavorable-Risk Prostate Cancer. JAMA Oncology, January 2017 DOI: 10.1001/jamaoncol.2016.5983

Friday, January 6, 2017

Mediterranean diet may have lasting effects on brain health

A new study shows that older people who followed a Mediterranean diet retained more brain volume over a three-year period than those who did not follow the diet as closely. The study is published in the January 4, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology. But contrary to earlier studies, eating more fish and less meat was not related to changes in the brain.
The Mediterranean diet includes large amounts of fruits, vegetables, olive oil, beans and cereal grains such as wheat and rice, moderate amounts of fish, dairy and wine, and limited red meat and poultry.
"As we age, the brain shrinks and we lose brain cells which can affect learning and memory," said study author Michelle Luciano, PhD, of the University of Edinburgh in Scotland. "This study adds to the body of evidence that suggests the Mediterranean diet has a positive impact on brain health."
Researchers gathered information on the eating habits of 967 Scottish people around age 70 who did not have dementia. Of those people, 562 had an MRI brain scan around age 73 to measure overall brain volume, gray matter volume and thickness of the cortex, which is the outer layer of the brain. From that group, 401 people then returned for a second MRI at age 76. These measurements were compared to how closely participants followed the Mediterranean diet.
The participants varied in how closely their dietary habits followed the Mediterranean diet principles. People who didn't follow as closely to the Mediterranean diet were more likely to have a higher loss of total brain volume over the three years than people who followed the diet more closely. The difference in diet explained 0.5 percent of the variation in total brain volume, an effect that was half the size of that due to normal aging.
The results were the same when researchers adjusted for other factors that could affect brain volume, such as age, education and having diabetes or high blood pressure.
There was no relationship between grey matter volume or cortical thickness and the Mediterranean diet.
The researchers also found that fish and meat consumption were not related to brain changes, which is contrary to earlier studies.
"It's possible that other components of the Mediterranean diet are responsible for this relationship, or that it's due to all of the components in combination," Luciano said.
Luciano noted that earlier studies looked at brain measurements at one point in time, whereas the current study followed people over time.
"In our study, eating habits were measured before brain volume was, which suggests that the diet may be able to provide long-term protection to the brain," said Luciano. "Still, larger studies are needed to confirm these results."

Story Source:
Materials provided by American Academy of Neurology (AAN). Note: Content may be edited for style and length.

Journal Reference:
  1. Michelle Luciano, Janie Corley, Simon R. Cox, Maria C. Valdés Hernández, Leone C.A. Craig, David Alexander Dickie, Sherif Karama, Geraldine M. McNeill, Mark E. Bastin, Joanna M. Wardlaw, Ian J. Deary. Mediterranean-type diet and brain structural change from 73 to 76 years in a Scottish cohort. Neurology, 2017; 10.1212/WNL.0000000000003559 DOI: 10.1212/WNL.0000000000003559

Autoimmunity and infections: When the body fights itself

Basel-based doctors are on the trail of a possible connection between autoimmune diseases and infections: errors can occur when immune cells absorb certain proteins from pathogen cells. These findings were reported in the journal PNAS by researchers from the Department of Biomedicine at the University of Basel and University Hospital Basel, as well as colleagues in the USA.
It is already known that there is a connection between infections and autoimmunity -- the inability of an organism to recognize parts of its own body as "self." As a result, increasing hygiene is leading to a higher incidence of autoimmune diseases in the population. It is also apparent that some autoimmune diseases are triggered by infections. However, the mechanism behind these connections is still not fully understood. One possible explanation is that the immune system confuses protein structures from pathogens with the body's own proteins because they look structurally alike.
Errors in protein uptake
Together with colleagues from the Whitehead Institute in Cambridge (USA), the Basel-based team of researchers tested out a new hypothesis in experiments to investigate the special ability of immune cells to identify specific proteins on the surface of neighboring cells and capture them from the cell membrane. In certain cases, errors can occur in the uptake of these proteins, as the group led by Professor Tobias Derfuss has now demonstrated.
Their assumption is that certain immune cells, so-called B cells, capture not only the protein of an influenza virus for which they were specialized but also small quantities of other neighboring membrane proteins. One example of this is a protein known as an autoantigen that originates from the cell membrane layer in the central nervous system. An immune response to this membrane protein results in an autoimmune inflammation in the brain in the animal model and may well also contribute to inflammation of this kind in humans.
Harmful immune cells
B cells cultivated with cells that had incorporated both the influenza virus protein and the membrane protein were not only able to activate other immune cells, specifically certain T cells, in order to combat the virus; they also activated T cells that had recognized the body's own membrane protein -- which can trigger autoimmune inflammation in the brain. Consequently, a viral infection could lead to the activation of autoaggressive T cells through an error in the protein uptake of B cells.
The researchers discovered this mechanism after conducting experiments using cells from genetically modified mice. "The next step would now be to examine whether similar errors occur in protein uptake by human B cells. We also want to clarify whether a viral infection in an animal can, under certain circumstances, lead to autoimmune inflammation in the brain," says Derfuss. Corresponding follow-up projects are planned.

Story Source:
Materials provided by Universität Basel. Note: Content may be edited for style and length.

Journal Reference:
  1. Sonal Thakar, Liqing Wang, Ting Yu, Mao Ye, Keisuke Onishi, John Scott, Jiaxuan Qi, Catarina Fernandes, Xuemei Han, John R. Yates, Darwin K. Berg, Yimin Zou. Evidence for opposing roles of Celsr3 and Vangl2 in glutamatergic synapse formation. Proceedings of the National Academy of Sciences, 2017; 201612062 DOI: 10.1073/pnas.1612062114

Research reveals help for eating disorder patients

More people are dying from eating disorders than any other psychiatric disorder, and one Cornell College professor has discovered a way to help women by significantly reducing eating disorder symptoms in those who are struggling.
Professor of Psychology Melinda Green and her team recently examined 47 women in Eastern Iowa who suffered from eating disorder symptoms, recruiting women through social media, fliers posted in practitioners' offices, local schools, and announcements in local media. The researchers used what's called a dissonance-based eating disorder program.
"Our intervention encourages women to criticize media messages which teach women and girls that we must be thin to be considered beautiful," said Green. "We also teach women and girls how to combat societal messages which teach us to define our worth in terms of our appearances."
The results from the four-week program reveal the importance of this type of treatment to help women.
"Women who took part in the program showed fewer eating disorder symptoms. Women also showed lower levels of anxiety and fewer negative emotions," Green said. "Women showed higher self-esteem and greater satisfaction with their bodies. They were less likely to idealize a thin body-type and less likely to define their self worth in terms of their appearance. They were also less likely to show several cardiac risk factors associated with eating disorders."
Green has worked for nearly a decade to research eating disorders. In her work, she has discovered a connection between eating disorders and cardiac risks, identifying markers of cardiac risk which worsen with eating disorder symptoms and improve with treatment. Her research has important implications for learning how to prevent and treat cardiac-related deaths in eating disorder patients. The results of this new study go even further to improve treatment and prevention options.
"Our work has a direct impact on the lives of women in Eastern Iowa since the program improves the lives of women who are struggling," Green said. "On a national and an international level, our results help to inform the best practices in eating disorder treatment and prevention. We are working alongside leading scientists across the world to improve this treatment and prevention paradigm to make it as effective as possible."
The psychology professor is currently conducting a treatment and prevention study and plans to pursue funding for another project to begin in the summer of 2017 to continue to refine this program. She consistently works with undergraduate students at Cornell College, who are involved in all phases of the research from revising the treatment programs to co-authoring manuscripts.
The Cornell College professor is also putting her own work into practice as she treats patients through a new online eating disorder prevention and treatment program.
Green is working with Tanager Place in nearby Cedar Rapids, Iowa, to continue her work. The group is currently fundraising to create a new, much-needed eating disorder treatment center for patients.

Story Source:
Materials provided by Cornell College. Note: Content may be edited for style and length.

Journal Reference:
  1. Green, Melinda A.; Willis, Mary; Fernandez-Kong, Kristen; Reyes, Shuhan; Linkhart, Ruby; Johnson, Molly; Thorne, Tyler; Kroska, Emily; Woodward, Halley; Lindberg, Jessica. Dissonance-Based Eating Disorder Program Reduces Cardiac Risk: A Preliminary Trial. Health Psychology, November 2016

Novel tests improve treatment for heart failure patients

For the first time, researchers have developed tests that could improve treatment for heart failure patients by diagnosing the condition with greater accuracy, as well as by detecting the onset of congestive heart failure earlier. The findings were published in the Cardiovascular Disease issue of Clinical Chemistry, the journal of AACC.
Heart failure occurs when the heart is weakened and can no longer pump blood adequately. There are numerous conditions that can damage the heart muscle and lead to heart failure, from coronary artery disease to diabetes to drug abuse, and in the U.S., it is the leading cause of hospitalization for people older than age 65. At present, the main blood tests used to aid in the diagnosis of heart failure are those for B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide (NT-proBNP). However, natriuretic peptide tests have a high false positive rate and a limited ability to detect the early and asymptomatic stages of the disease.
With the goal of overcoming the drawbacks of current heart failure tests, a group of researchers developed a diagnostic panel that provides a more comprehensive representation of the heart's functioning by measuring multiple biological molecules. Led by Hugo A. Katus, MD, PhD, of Heidelberg University Hospital in Heidelberg, Germany, the researchers began by identifying 92 metabolites -- or byproducts of the body's metabolism -- that changed significantly in heart failure patients compared with healthy individuals. They chose three of these metabolites that belong to the lipid classes of sphingomyelins, triglycerides, and phosphatidylcholines for their cardiac lipid panel (CLP).
In a second confirmation study, the researchers then tested the ability of CLP combined with NT-proBNP measurements to diagnose heart failure in 649 individuals who either had the condition, were healthy, or had pulmonary diseases (which can often be confused with heart failure). CLP plus NT-proBNP diagnosed heart failure with much greater certainty than NT-proBNP alone, even in the early and asymptomatic stages, demonstrating a high specificity of 97.6% while NT-proBNP by itself only has a specificity of 88.1%.
"A low false-positive rate is particularly important in the outpatient setting and may prevent patients from unnecessary diagnostic workup and treatment, which in turn will save resources and avoid potential side-effects," said Katus. "A more accurate diagnosis of patients with early and intermediate […] and mild or asymptomatic systolic dysfunction as observed with the novel panel compared to NT-proBNP alone may accelerate adequate pharmacological or behavioral treatments for the reduction of mortality and morbidity in these patients."
Heart failure can also progress to congestive heart failure, which occurs when fluid builds up in the limbs, lungs, and/or other organs as an indirect result of the heart's weakened pumping. Systemic congestion is a major determinant of organ dysfunction and death in chronic heart failure patients. Currently, there is no reliable test that can diagnose congestion in its pre-symptomatic stages, which is needed so that healthcare providers can start or adjust decongestive therapy for patients before the condition worsens.
In this paper, a group of researchers led by Alexandre Mebazaa, MD, of Université Paris Diderot show that a test for the protein soluble CD146 (sCD146) could potentially detect congestion early. One of the initial signs of congestion is a subclinical increase of venous pressures. To demonstrate that sCD146 is released as a response to this, the researchers compressed the dominant arm of 44 stable chronic heart failure patients and measured sCD146 levels in both arms at the start time and after 90 minutes. In the compressed arm, sCD146 levels increased significantly by 60 µg/L compared with a small 16 µg/L increase in the control arm. These results indicate that, if validated in larger studies, sCD146 could serve as a marker of the increased venous pressure that signals the onset of congestion.

Story Source:
Materials provided by American Association for Clinical Chemistry (AACC). Note: Content may be edited for style and length.

Journal Reference:
  1. Mattia Arrigo, Quynh A. Truong, Duygu Onat, Jackie Szymonifka, Etienne Gayat, Heli Tolppanen, Malha Sadoune, Ryan T. Demmer, Ka Y. Wong, Jean Marie Launay, Jane-Lise Samuel, Alain Cohen-Solal, James L. Januzzi, Jagmeet P. Singh, Paolo C. Colombo, Alexandre Mebazaa. Soluble CD146 Is a Novel Marker of Systemic Congestion in Heart Failure Patients: An Experimental Mechanistic and Transcardiac Clinical Study. Clinical Chemistry, 2017; 63 (1): 386 DOI: 10.1373/clinchem.2016.260471

Using fat to help wounds heal without scars

Doctors have found a way to manipulate wounds to heal as regenerated skin rather than scar tissue. The method involves transforming the most common type of cells found in wounds into fat cells -- something that was previously thought to be impossible in humans. Researchers began this work at the Perelman School of Medicine at the University of Pennsylvania, which led to a large-scale, multi-year study in connection with the Plikus Laboratory for Developmental and Regenerative Biology at the University of California, Irvine. They published their findings online in the journal Science on Thursday, January 5th, 2017.
Fat cells called adipocytes are normally found in the skin, but they're lost when wounds heal as scars. The most common cells found in healing wounds are myofibroblasts, which were thought to only form a scar. Scar tissue also does not have any hair follicles associated with it, which is another factor that gives it an abnormal appearance from the rest of the skin. Researchers used these characteristics as the basis for their work -- changing the already present myofibroblasts into fat cells that do not cause scarring.
"Essentially, we can manipulate wound healing so that it leads to skin regeneration rather than scarring," said George Cotsarelis, MD, the chair of the Department of Dermatology and the Milton Bixler Hartzell Professor of Dermatology at Penn, and the principal investigator of the project. "The secret is to regenerate hair follicles first. After that, the fat will regenerate in response to the signals from those follicles."
The study showed hair and fat develop separately but not independently. Hair follicles form first, and the Cotsarelis lab previously discovered factors necessary for their formation. Now they've discovered additional factors actually produced by the regenerating hair follicle to convert the surrounding myofibroblasts to regenerate as fat instead of forming a scar. That fat will not form without the new hairs, but once it does, the new cells are indistinguishable from the pre-existing fat cells, giving the healed wound a natural look instead of leaving a scar. As they examined the question of what was sending the signal from the hair to the fat cells, researchers identified a factor called Bone Morphogenetic Protein (BMP). It instructs the myofibroblasts to become fat. This signaling was groundbreaking on its own, as it changed what was previously known about myofibroblasts.
"Typically, myofibroblasts were thought to be incapable of becoming a different type of cell," Cotsarelis said. "But our work shows we have the ability to influence these cells, and that they can be efficiently and stably converted into adipocytes." This was shown in both the mouse and in human keloid cells grown in culture.
"The findings show we have a window of opportunity after wounding to influence the tissue to regenerate rather than scar," said the study's lead author Maksim Plikus, PhD, an assistant professor of Developmental and Cell Biology at the University of California, Irvine. Plikus began this research as a postdoctoral fellow in the Cotsarelis Laboratory at Penn, and the two institutions have continued to collaborate.
These discoveries have the potential to be revolutionary in the field of dermatology. The first and most obvious use would be to develop a therapy that signals myofibroblasts to convert into adipocytes -- helping wounds heal without scarring.
"It's highly desirable from a clinical standpoint, but right now it's an unmet need," Cotsarelis said.
But the increase of fat cells in tissue can also be helpful for more than just wounds. Adipocyte loss is a common complication of other conditions, especially treatments for HIV, and right now there is no efficient strategy for treatment. The cells are also lost naturally because of the aging process, especially in the face, which leads to permanent, deep wrinkles, something anti-aging treatments can't fix in a cosmetically satisfactory way.
"Our findings can potentially move us toward a new strategy to regenerate adipocytes in wrinkled skin, which could lead us to brand new anti-aging treatments," Cotsarelis said.
The Cotsarelis Lab is now focusing on the mechanisms that promote skin regeneration, especially with respect to hair follicle regeneration.
The Plikus Laboratory is focusing on other aspects of cell reprogramming in skin wounds. Researchers there are examining the role of other signaling factory beyond BMP as well as conducting further studies using human cells and human scar tissue.

Story Source:
Materials provided by University of Pennsylvania School of Medicine. Note: Content may be edited for style and length.

Journal Reference:
  1. Maksim V. Plikus, Christian F. Guerrero-Juarez, Mayumi Ito, Yun Rose Li, Priya H. Dedhia, Ying Zheng, Mengle Shao, Denise L. Gay, Raul Ramos, Tsai-Ching His, Ji Won Oh, Xiaojie Wang, Amanda Ramirez, Sara E. Konopelski, Arijh Elzein, Anne Wang, Rarinthip June Supapannachart, Hye-Lim Lee, Chae Ho Lim, Arben Nace, Amy Guo, Elsa Treffeisen, Thomas Andl, Ricardo N. Ramirez, Rabi Murad, Stefan Offermanns, Daniel Metzger, Pierre Chambon, Alan D. Widgerow, Tai-Lan Tuan, Ali Mortazavi, Rana K. Gupta, Bruce A. Hamilton, Sarah E. Millar, Patrick Seale, Warren S. Pear, Mitchell A. Lazar, George Cotsarelis. Regeneration of fat cells from myofibroblasts during wound healing. Science, 2017 DOI: 10.1126/science.aai8792